Abstract
Hepatitis C virus (HCV) infection affects about 160 million people worldwide. It is treated with pegylatedinterferon (peg-IFN) and ribavirin, and in the case of patients affected by genotype 1, also with a protease inhibitor (telaprevir or boceprevir). Despite a good success rate, IFN-based combinations are contraindicated in several patients (e.g. decompensated cirrhosis, patients with psychiatric disorders, severe heart diseases or autoimmune disorders) and are associated with frequent adverse events that ultimately reduce their use. Numerous oral drugs are in an advanced phase of clinical development, and in some cases, in IFN-free combinations. This review focuses on preclinical and clinical data regarding daclatasvir (BMS-790052), which is a highly selective HCV NS5A replication complex inhibitor effective against HCV genotypes 1, 2, 3 and 4. In vitro data show that daclatasvir exerts a very potent antiviral effect against several HCV genotypes. Its pharmacokinetics is optimal and allows once-a-day oral administration. Its adverse event profile is good. Clinical data regarding its efficacy in combination with peg-IFN, ribavirin or other direct antiviral agents are impressive (rates of sustained virological response range between 60% and 100% in treatment-naïve patients). The only drawback of this drug appears to be a relatively low genetic barrier to resistance. In conclusion, daclatasvir, especially in combinations with other antiviral agents, is a very promising drug for the treatment of chronic hepatitis C.
Keywords: Combination therapy, daclatasvir, hepatitis C virus, Interferon-free, pegylated-interferon, polymerase inhibitors, resistance, ribavirin.
Current Medicinal Chemistry
Title:Daclatasvir: The First of a New Class of Drugs Targeted Against Hepatitis C Virus NS5A
Volume: 21 Issue: 12
Author(s): I. Gentile, F. Borgia, N. Coppola, A.R. Buonomo, G. Castaldo and G. Borgia
Affiliation:
Keywords: Combination therapy, daclatasvir, hepatitis C virus, Interferon-free, pegylated-interferon, polymerase inhibitors, resistance, ribavirin.
Abstract: Hepatitis C virus (HCV) infection affects about 160 million people worldwide. It is treated with pegylatedinterferon (peg-IFN) and ribavirin, and in the case of patients affected by genotype 1, also with a protease inhibitor (telaprevir or boceprevir). Despite a good success rate, IFN-based combinations are contraindicated in several patients (e.g. decompensated cirrhosis, patients with psychiatric disorders, severe heart diseases or autoimmune disorders) and are associated with frequent adverse events that ultimately reduce their use. Numerous oral drugs are in an advanced phase of clinical development, and in some cases, in IFN-free combinations. This review focuses on preclinical and clinical data regarding daclatasvir (BMS-790052), which is a highly selective HCV NS5A replication complex inhibitor effective against HCV genotypes 1, 2, 3 and 4. In vitro data show that daclatasvir exerts a very potent antiviral effect against several HCV genotypes. Its pharmacokinetics is optimal and allows once-a-day oral administration. Its adverse event profile is good. Clinical data regarding its efficacy in combination with peg-IFN, ribavirin or other direct antiviral agents are impressive (rates of sustained virological response range between 60% and 100% in treatment-naïve patients). The only drawback of this drug appears to be a relatively low genetic barrier to resistance. In conclusion, daclatasvir, especially in combinations with other antiviral agents, is a very promising drug for the treatment of chronic hepatitis C.
Export Options
About this article
Cite this article as:
Gentile I., Borgia F., Coppola N., Buonomo A.R., Castaldo G. and Borgia G., Daclatasvir: The First of a New Class of Drugs Targeted Against Hepatitis C Virus NS5A, Current Medicinal Chemistry 2014; 21 (12) . https://dx.doi.org/10.2174/0929867321666131228222215
DOI https://dx.doi.org/10.2174/0929867321666131228222215 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Gene Therapy in Cardiovascular Diseases
Current Gene Therapy Role of PPAR-γ Agonist Thiazolidinediones in Treatment of Pre-Diabetic and Diabetic Individuals: A Cardiovascular Perspective
Current Drug Targets - Cardiovascular & Hematological Disorders Editorial [Hot Topic:Modifying Cardiovascular Risk Factors: Newer Insights and Preventive Measures (Executive Editor: Aurelio Leone)]
Current Pharmaceutical Design Effects of CYP2C19 Polymorphism on Endothelial Function, Arterial Stiffness and Inflammation in Coronary Artery Disease Patients Under Clopidogrel Treatment
Current Pharmaceutical Design Single-cell RNA Sequencing: In-depth Decoding of Heart Biology and Cardiovascular Diseases
Current Genomics Occupational Respiratory Pathology in Russia: Current Trends and Challenges
Current Respiratory Medicine Reviews Role of Heart Rate Reduction in the Management of Myocarditis
Current Pharmaceutical Design Elevated Heart Rate, A Risk Factor and Risk Marker of Cardiovascular Disease
Current Hypertension Reviews Structural Characterization, Biological Effects, and Synthetic Studies on Xanthones from Mangosteen (Garcinia mangostana), a Popular Botanical Dietary Supplement
Mini-Reviews in Organic Chemistry Evaluation of Ischemic Heart Disease Factors in Hemophilia Patients in Khorramabad
Cardiovascular & Hematological Disorders-Drug Targets Functional Non-Synonymous Polymorphisms Prediction Methods: Current Approaches and Future Developments
Current Medicinal Chemistry Role of Isoprenoid Compounds on Angiogenic Regulation: Opportunities and Challenges
Current Medicinal Chemistry Aβ Monomers, Oligomers and Fibrils: Structural Features
Current Bioactive Compounds Cell Immunity in Coronary Artery Disease (CAD)
Current Immunology Reviews (Discontinued) Can Imaging Techniques Identify Smoking-Related Cardiovascular Disease?
Current Pharmaceutical Design Pharmacotherapy for Obesity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Future Therapeutic Strategies in Inflammatory Cardiomyopathy: Insights from the Experimental Autoimmune Myocarditis Model
Cardiovascular & Hematological Disorders-Drug Targets Dysregulation of SIRT-1 Signaling in Multiple Sclerosis and Neuroimmune Disorders: A Systematic Review of SIRTUIN Activators as Potential Immunomodulators and their Influences on other Dysfunctions
Endocrine, Metabolic & Immune Disorders - Drug Targets Zinc and Cell Signaling During Inflammation: Implications in Atherosclerosis
Current Nutrition & Food Science The Etiology of Hypertension in the Metabolic Syndrome Part One: An Introduction to the History, the Concept and the Models
Current Vascular Pharmacology